Genetic variation in UGT1A1 is not associated with altered liver biochemical parameters in healthy volunteers participating in bioequivalence trials
Introduction: Bioequivalence clinical trials are conducted in healthy volunteers whose blood tests should be within normal limits; individuals with Gilbert syndrome (GS) are excluded from these studies on suspicion of any liver disease, even if the change is clinically insignificant. GS is a benign...
Saved in:
Main Authors: | Eva González-Iglesias (Author), Dolores Ochoa (Author), Manuel Román (Author), Paula Soria-Chacartegui (Author), Samuel Martín-Vilchez (Author), Marcos Navares-Gómez (Author), Alejandro De Miguel (Author), Pablo Zubiaur (Author), Andrea Rodríguez-Lopez (Author), Francisco Abad-Santos (Author), Jesús Novalbos (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2024-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Impact of polymorphisms in CYP and UGT enzymes and ABC and SLCO1B1 transporters on the pharmacokinetics and safety of desvenlafaxine
by: Sofía Calleja, et al.
Published: (2023) -
An Investigational Study on the Role of <i>CYP2D6</i>, <i>CYP3A4</i> and <i>UGT</i>s Genetic Variation on Fesoterodine Pharmacokinetics in Young Healthy Volunteers
by: Andrea Rodríguez-Lopez, et al.
Published: (2024) -
Genetic Variation in <i>CYP2D6</i>, <i>UGT1A4</i>, <i>SLC6A2</i> and <i>SLCO1B1</i> Alters the Pharmacokinetics and Safety of Mirabegron
by: Paula Soria-Chacartegui, et al.
Published: (2024) -
Dexketoprofen Pharmacokinetics is not Significantly Altered by Genetic Polymorphism
by: Gina Mejía-Abril, et al.
Published: (2021) -
Evaluation of the role of metabolizing enzymes and transporter variants in ezetimibe pharmacokinetics
by: Eva González-Iglesias, et al.
Published: (2024)